Factors associated with mortality in patients with tuberculosis

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Horne, David J ^a   Hubbard, Rebecca ^b,c   Narita, Masahiro ^a,c,d   Exarchos, Alexia ^e   Park, David R ^a   Goss, Christopher H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^e WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; STREPTOMYCIN;

ADULT; AGING; ARTICLE; CAUSE OF DEATH; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH CERTIFICATE; DEMOGRAPHY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; SEX DIFFERENCE; UNITED STATES; AGED; HEALTH CARE PERSONNEL; MIDDLE AGED; RISK FACTOR; STATISTICS; TUBERCULOSIS;

ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH PERSONNEL; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS; WASHINGTON;

EID: 77955946441     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-258     Document Type: Article

References (24)

1. Global Tuberculosis Programme Global tuberculosis control: WHO report. 2009, Geneva: Global Tuberculosis Programme World Health Organization, vol. Began with 1997, Global Tuberculosis Programme.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282(7):677-686. 10.1001/jama.282.7.677, 10517722.
3. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6(12):1114-1117.
4. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006, 28(5):980-985. 10.1183/09031936.06.00125705, 16837502.
5. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004, 169(10):1103-1109. 10.1164/rccm.200308-1159OC, 14742301.
6. van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, Sabally S, Jeffries D, Adegbola RA, Sarge-Njie R, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004, 18(14):1933-1941. 10.1097/00002030-200409240-00009, 15353979.
7. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996, 276(15):1223-1228. 10.1001/jama.276.15.1223, 8849749.
8. Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M, Vernon A. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 2006, 10(5):542-549.
9. Anyama N, Bracebridge S, Black C, Niggebrugge A, Griffin SJ. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect 2007, 135(7):1069-1076. 10.1017/S0950268807007996, 2870683, 17288641.
10. Low S, Ang LW, Cutter J, James L, Chee CB, Wang YT, Chew SK. Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis 2009, 13(3):328-334.
11. Khan K, Campbell A, Wallington T, Gardam M. The impact of physician training and experience on the survival of patients with active tuberculosis. CMAJ 2006, 175(7):749-753. 1569931, 17001055.
12. http://wonder.cdc.gov/tb.html
13. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1993, 42(RR-7):1-8.
14. Horne DJ, Hubbard R, Narita M, Exarchos A, Goss CH. Survival following a diagnosis of tuberculosis in Washington State. Am J Respir Crit Care Med 2009, 179:A5281.
15. Curtis AB ME, McKenna M, et al. Completeness and timeliness of tuberculosis case reporting, a multistate study. Am J Prev Med 2001, 20:108-112. 10.1016/S0749-3797(00)00284-1, 11165451.
16. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005, 172(9):1169-1227. 10.1164/rccm.2508001, 16249321.
17. TIMS User's Guide, Appendix SUR I - RVCT Form Completion Instructions. 2003, , http://wonder.cdc.gov/wonder/help/TB/RVCTFormCompletionInstructions.pdf
18. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001, 33(10):1762-1769. 10.1086/323784, 11595988.
19. Singh GK MB. Health, life expectancy, and mortality patterns among immigrant populations in the United States. Canadian J Pub Health 2004, 95:I14-21.
20. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994, 330(17):1179-1184. 10.1056/NEJM199404283301702, 8139628.
21. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004, 170(5):561-566. 10.1164/rccm.200401-095OC, 15184210.
22. Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C, Punnachest K, Na-Songkhla S, Payanandana V. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999, 93(5):552-557. 10.1016/S0035-9203(99)90379-6, 10696421.
23. Cayla JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, Garcia JM, Blanquer R, Casals M. Tuberculosis treatment adherence and fatality in Spain. Respir Res 2009, 10:121. 10.1186/1465-9921-10-121, 2794858, 19951437.
24. Coady SA, Sorlie PD, Cooper LS, Folsom AR, Rosamond WD, Conwill DE. Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Epidemiol 2001, 54(1):40-50. 10.1016/S0895-4356(00)00272-9, 11165467.